Further studies are still needed to fully investigate the efficacy of interfering HIF‐1α/METTL14/YTHDF2/SLC7A11 axis with small molecule or gene therapy in clinic to better advance the HCC interventional embolization treatment. This evidence concerns the gene YTHDF2 and hepatocellular carcinoma.